USU-Walter Reed Department of Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland.
J Bone Joint Surg Am. 2021 Apr 21;103(8):681-687. doi: 10.2106/JBJS.20.01005.
Targeted muscle reinnervation (TMR) and regenerative peripheral nerve interface (RPNI) procedures have been shown to improve patient-reported outcomes for the treatment of symptomatic neuromas after amputation; however, the specific indications and comparative outcomes of each are unclear. The primary research questions were what complement of nerves most frequently requires secondary pain intervention after conventional amputation, whether this information can guide the focused application of TMR and RPNI to the primary amputation setting, and how the outcomes compare in both settings.
We performed a retrospective review of records for patients who had undergone lower-extremity TMR and/or RPNI at our institution. Eighty-seven procedures were performed: 59 for the secondary treatment of symptomatic neuroma pain after amputation and 28 for primary prophylaxis during amputation. We reviewed records for the amputation level, TMR and/or RPNI timing, pain scores, patient-reported resolution of nerve-related symptoms, and complications or revisions. We evaluated the relationship between the amputation level and the frequency with which each transected nerve required neurologic intervention for pain symptoms.
The mean pain score decreased after delayed TMR or RPNI procedures from 4.3 points to 1.7 points (p < 0.001), and the mean final pain score (and standard deviation) was 1.0 ± 1.9 points at the time of follow-up for acute procedures. Symptom resolution was achieved in 92% of patients. The sciatic nerve most commonly required intervention for symptomatic neuroma above the knee, and the tibial nerve and common or superficial peroneal nerve were most problematic following transtibial amputation. None of our patients required a revision pain treatment procedure after primary TMR targeting these commonly symptomatic nerves. Failure to address the tibial nerve during a delayed procedure was associated with an increased risk of unsuccessful TMR, resulting in a revision surgical procedure (odds ratio, 26 [95% confidence interval, 1.8 to 368]; p = 0.02).
There is a consistent pattern of symptomatic nerves that require secondary surgical intervention for the management of pain after amputation. TMR and RPNI were translated to the primary amputation setting by using this predictable pattern to devise a surgical strategy that prevents symptomatic neuroma pain.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
靶向肌肉神经再支配(TMR)和再生周围神经接口(RPNI)技术已被证明可改善截肢后症状性神经瘤患者的报告结局;然而,每种技术的具体适应证和比较结果尚不清楚。主要研究问题是:在常规截肢后,哪种神经最常需要二次疼痛干预;这些信息是否可以指导 TMR 和 RPNI 在初次截肢时的集中应用;以及在这两种情况下的结果比较。
我们对在我院接受下肢 TMR 和/或 RPNI 治疗的患者记录进行了回顾性分析。共进行了 87 例手术:59 例用于治疗截肢后症状性神经瘤疼痛的二次治疗,28 例用于截肢时的初级预防。我们查阅了截肢水平、TMR 和/或 RPNI 时机、疼痛评分、患者报告的神经相关症状缓解情况以及并发症或修订情况。我们评估了截肢水平与每种切断神经需要进行神经干预以缓解疼痛症状的频率之间的关系。
延迟 TMR 或 RPNI 手术后,平均疼痛评分从 4.3 分降至 1.7 分(p < 0.001),急性手术时的平均最终疼痛评分(和标准差)为 1.0 ± 1.9 分。92%的患者症状得到缓解。坐骨神经在膝关节以上的症状性神经瘤最常需要干预,而胫神经和腓总神经或腓浅神经在经胫骨截肢后最成问题。我们的患者在初次 TMR 靶向这些常见症状性神经时,均无需进行修订的疼痛治疗。延迟手术中未处理胫神经与 TMR 失败相关,导致需要进行修订的手术程序(比值比,26 [95%置信区间,1.8 至 368];p = 0.02)。
有一个一致的模式,即需要对截肢后疼痛进行二次手术干预的症状性神经。TMR 和 RPNI 通过使用这种可预测的模式应用于初次截肢,制定了一种防止症状性神经瘤疼痛的手术策略。
治疗性 IV 级。有关证据等级的完整描述,请参见作者说明。